BioPharma Dive March 12, 2025
Élancé Therapeutics was created to develop bispecific antibody drugs for weight loss. Elsewhere, Gilead is readying a new Phase 3 study of lenacapavir.
Today, a brief rundown of news involving Harbour BioMed and Gilead Sciences, as well as updates from Geron, Biogen and Genmab that you may have missed.
Harbour BioMed on Wednesday launched a new biotechnology company, Élancé Therapeutics, that will develop bispecific antibody drugs for obesity. Elance will prioritize advancing therapies that can address the shortcomings of current weight loss medicines, such as by better preserving muscle or providing more durable benefits. Muscle mass preservation has become a new focus for the obesity field as other biotechs trying to develop weight-loss drugs that can compete with Novo...
Today's Sponsors
Today's Sponsor